MedTrace Logo

Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease

NCT00598962 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-05-23

No results posted yet for this study

Summary

To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)

Conditions

  • Mycobacterium Avium Complex

Interventions

DRUG

Azithromycin

Dosage dependent on clinical factors such as age, weight and patient-specific health status

DRUG

Rifabutin/rifampin

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • The University of Texas Health Science Center at Tyler

    lead OTHER

Principal Investigators

  • Richard J Wallace Jr., M.D. · The University of Texas Health Science Center at Tyler

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-12-31
Primary Completion
2006-11-30
Completion
2017-05-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00598962 on ClinicalTrials.gov